Ropivacaine Hydrochloride Injection USP, 0.5%, 150mg/30 mL (5 mg/mL), 30 mL Single-dose Vial, Rx ...

FDA Recall #D-0842-2023 — Class II — April 26, 2023

Recall #D-0842-2023 Date: April 26, 2023 Classification: Class II Status: Ongoing

Product Description

Ropivacaine Hydrochloride Injection USP, 0.5%, 150mg/30 mL (5 mg/mL), 30 mL Single-dose Vial, Rx Only, Manufactured by: Akorn Inc., Lake Forest, IL 60045. ALL NDCs

Reason for Recall

CGMP Deviations: Firm went out of business and could no longer continue stability studies.

Recalling Firm

Akorn, Inc. — Gurnee, IL

Classification

Class II — May cause temporary or medically reversible adverse health consequences.

Product Type

Drugs

Product Quantity

N/A

Distribution

Nationwide in the USA and Puerto Rico

Code Information

All Lots

Status

Ongoing

Voluntary / Mandated

Voluntary: Firm initiated